430 related articles for article (PubMed ID: 17512356)
1. Statins targeting inflammation by lowering low-density lipoprotein?
Tuzcu EM; Nicholls SJ
J Am Coll Cardiol; 2007 May; 49(20):2010-2. PubMed ID: 17512356
[No Abstract] [Full Text] [Related]
2. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
Kinlay S
J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
[TBL] [Abstract][Full Text] [Related]
3. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
[TBL] [Abstract][Full Text] [Related]
4. LDL-Cholesterol is the King.
Goumas GS
Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
[No Abstract] [Full Text] [Related]
5. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
6. [On the current debate on lowering LDL cholesterol with ezetimibe].
Breuer HW
Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
[No Abstract] [Full Text] [Related]
7. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
[No Abstract] [Full Text] [Related]
8. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
9. Optimal lipids, statins, and dementia.
Lavie CJ; Milani RV
J Am Coll Cardiol; 2005 Mar; 45(6):963-4; author reply 964-5. PubMed ID: 15766838
[No Abstract] [Full Text] [Related]
10. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
Mascitelli L; Pezzetta F; Goldstein MR
Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735
[TBL] [Abstract][Full Text] [Related]
11. [Statins remain the standard. New methods for lipid lowering therapy].
Aumiller J
MMW Fortschr Med; 2001 Oct; 143(42):16-7. PubMed ID: 11697281
[No Abstract] [Full Text] [Related]
12. [New results in the management of hypercholesterolemia].
Sármán B
Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867
[TBL] [Abstract][Full Text] [Related]
13. [LDL cholesterol in cardiovascular risk patients should be as low as possible].
MMW Fortschr Med; 2007 Oct; 149(41):44-5. PubMed ID: 17992793
[No Abstract] [Full Text] [Related]
14. Clinical trials and tribulations. Cholesterol veers off script.
Couzin J
Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
[No Abstract] [Full Text] [Related]
15. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Weizel A; Sawicki PT
MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
[No Abstract] [Full Text] [Related]
16. Ezetimibe offers new opportunity to lower LDL-C to target levels.
Cardiovasc J S Afr; 2005; 16(3):174. PubMed ID: 16049593
[No Abstract] [Full Text] [Related]
17. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study.
Pauriah M; Struthers AD; Lang CC
Cardiovasc Ther; 2008; 26(2):85-8. PubMed ID: 18485130
[No Abstract] [Full Text] [Related]
18. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
19. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
Ballantyne CM
Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
[TBL] [Abstract][Full Text] [Related]
20. The power of statins: aggressive lipid lowering.
Jones PH
Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
